Evidence map›Paper›PMID 40246811›Full record

ArticleBlood cancer journal2025

Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma.

Cecilia Larocca, Ai-Tram N Bui, John T O'Malley, Anita Giobbie-Hurder, Marianne Tawa, Jessica E Teague, Rachael A Clark, Corey Cutler, Eric Jacobsen, David C Fisher and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Cecilia Larocca *Harvard Medical School, Boston, MA, USA.
Ai-Tram N Bui *Harvard Medical School, Boston, MA, USA.
John T O'MalleyHarvard Medical School, Boston, MA, USA.
Anita Giobbie-HurderDivision of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Marianne TawaDepartment of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
Jessica E TeagueDepartment of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
Rachael A ClarkHarvard Medical School, Boston, MA, USA.
Corey CutlerDepartment of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8728-4314
Eric JacobsenDepartment of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.
David C FisherDepartment of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6915-8584
Thomas S KupperHarvard Medical School, Boston, MA, USA.
Nicole R LeBoeufHarvard Medical School, Boston, MA, USA. nleboeuf@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-8264-834X

Funding

Transforming the diagnosis and care of patients with CTCL using TCR sequencingR01CA203721 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN, KUPPER, THOMAS S. · 2016 to 2020
$3.4M
Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphomaU01CA253190 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN · 2020 to 2024
$2.1M
NCI NIH HHS R01 CA203721NCI NIH HHS U01 CA253190
6 · The paper itself

Abstract

Cutaneous T-cell lymphomas (CTCL) have in common malignant T-lymphocyte infiltration in the skin. Low dose alemtuzumab (LDA) appears to be an effective treatment for leukemic disease, but in the absence of clinical trials, there is need for improved characterization of patients with CTCL most likely to benefit. A retrospective cohort study of 38 patients with CTCL treated with LDA with at least 5 years' follow-up data was conducted. As a surrogate for a central memory T-cell (T

Indexed as

AlemtuzumabAntineoplastic Agents, ImmunologicalLymphoma, T-Cell, CutaneousSkin NeoplasmsAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMemory T CellsMiddle AgedPhenotypeRetrospective StudiesTreatment OutcomeAlemtuzumabAntineoplastic Agents, Immunological

Identifiers

PMID40246811
PMCPMC12006509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.